Highest-materiality recent filing
Burzynski Research expects to miss 10-K filing; majority owner stops funding SEC costs
Dr. Stanislaw Burzynski, beneficial owner of majority of BZYR common stock, will not fund SEC reporting costs due to limited resources.
CFO Patryk P. Goscianski resigns; CEO Stanislaw R. Burzynski appointed CFO and Secretary
Patryk P. Goscianski resigned as CFO and Secretary on April 16, effective April 17, 2026; no disagreement cited.
BZYR licenses antineoplaston patents from CEO; research funding secured through Feb 2024
License from Dr. Burzynski for exclusive rights to four US patents and pending applications for antineoplastons in US/Canada.
On April 6, 2023, Carlton Hazlewood, a member of the board of directors (the “Board”) of Burzynski Research Institute, Inc. (the “Company”), notified the Company of his decision to resign from the Board effective immediately.
On October 6, 2021, the board of directors (the “Board”) of Burzynski Research Institute, Inc. (the “Company”) appointed Monika Szopa-Paszkowiak to the Board, to fill a vacancy as a result of the passing away of Dr. Barbara Burzynski, effective as of the same date
to fill a vacancy as a result of the passing away of Dr. Barbara Burzynski
Max materiality 0.90 · Median 0.40 · Most common event other_material